Novartis wins world-first Cosentyx approval in Japan
This article was originally published in Scrip
Executive Summary
Novartis has won its first worldwide approval for its anti-inflammatory Cosentyx (secukinumab), with Japanese authorities issuing the nod in both psoriasis and psoriatic arthritis.